Perbedaan Kadar Aspartate Aminotransferase dan Alanine Aminotransferase Berdasarkan Kelebihan Zat Besi pada Pasien Talasemia Beta Mayor
Sari
ABSTRACT
Beta thalassemia major patients require repeated transfusions, which increase the risk of iron overload. Iron accumulation mainly occurs in the liver and may cause hepatocellular damage, reflected by elevated transaminase enzymes, namely Aspartate Aminotransferase (AST) and alanine aminotransferase (ALT). Serum ferritin is commonly used as an indicator of body iron stores; however, the relationship between ferritin levels and changes in AST and ALT remains inconsistent. This study aimed to determine differences in AST and ALT levels based on iron overload status in patients with beta-thalassemia major.This was an analytic observational study with a cross-sectional design conducted at M. Djamil Hospital, Padang, from March to August 2025. The study included 36 pediatric patients with beta-thalassemia major who met the inclusion and exclusion criteria, selected using consecutive sampling. Iron overload was classified based on serum ferritin levels: <1,000 μg/L as non-risk and ≥1,000 μg/L as at-risk. Statistical analysis was performed using computer software. Numerical data were presented as median (minimum–maximum) and analyzed using the Mann–Whitney test with a significance level of p<0.05. Median AST level was 40.50 U/L (22–191 U/L), and median ALT level was 32.50 U/L (7–220 U/L). Aspartate aminotransferase levels were significantly higher in the at-risk group compared to the non-risk group (p=0.020). Alanine aminotransferase levels were also significantly higher in the at-risk group (p=0.009).There were significant differences in AST and ALT levels based on iron overload in beta thalassemia major patients, indicating hepatic involvement due to iron accumulation.
Keywords: Beta Thalassaemia Major, Ferritin, Aspartate Aminotransferase, Alanine Aminotransferase.
ABSTRAK
Pasien talasemia beta mayor memerlukan transfusi darah berulang yang berisiko menyebabkan kelebihan zat besi. Akumulasi besi terutama terjadi di hati dan dapat menimbulkan kerusakan hepatoseluler yang ditandai dengan peningkatan kadar enzim transaminase, yaitu aspartate aminotransferase (AST) dan alanine aminotransferase (ALT). Kadar feritin serum digunakan sebagai indikator cadangan besi tubuh, namun hubungan antara kadar feritin dengan perubahan AST dan ALT masih menunjukkan hasil yang bervariasi. Penelitian ini bertujuan untuk mengetahui perbedaan kadar aspartate aminotransferase (AST) dan alanine aminotransferase (ALT) berdasarkan status kelebihan zat besi yang dinilai dari kadar feritin serum pada pasien anak dengan talasemia beta mayor di RS M. Djamil Padang.Penelitian ini merupakan penelitian observasional analitik dengan rancangan potong lintang yang dilakukan di RS M. Djamil Padang pada periode Maret–Agustus 2025. Subjek penelitian terdiri dari 36 pasien anak talasemia beta mayor yang memenuhi kriteria inklusi dan eksklusi, diambil dengan metode consecutive sampling. Kelebihan zat besi ditentukan berdasarkan kadar feritin serum <1.000 μg/L sebagai tidak berisiko dan ≥1.000 μg/L sebagai berisiko. Analisis statistik dilakukan menggunakan program komputer. Data numerik disajikan dalam bentuk median (minimum–maksimum) dan dianalisis menggunakan uji Mann–Whitney dengan batas kemaknaan p<0,05. Median kadar AST adalah 40,50 U/L (22–191 U/L) dan median kadar ALT adalah 32,50 U/L (7–220 U/L). Kadar AST pada kelompok berisiko lebih tinggi dibandingkan kelompok tidak berisiko (p=0,020). Kadar ALT pada kelompok berisiko juga secara signifikan lebih tinggi dibandingkan kelompok tidak berisiko (p=0,009). Terdapat perbedaan bermakna kadar AST dan ALT berdasarkan kelebihan zat besi pada pasien talasemia beta mayor, yang menunjukkan adanya keterlibatan fungsi hati akibat penimbunan besi.
Kata Kunci: Talasemia Beta Mayor, Feritin, Aspartate Aminotransferase, Alanine Aminotransferase.
Teks Lengkap:
Download ArtikelReferensi
## Daftar Pustaka
Abbas, A. B., Yahya, A., Aloqab, Z., Alhudhaifi, A., Alateef, A. A., Morshed, A., et al. (2025). Determination of reference intervals for common liver function tests among healthy adults. *Scientific Reports, 15*, 12896.
Abbott Laboratories. (2021). *Aspartate aminotransferase2 for use with Alinity c system: Package insert*. Abbott Park, IL.
Agustina, R., Mandala, Z., & Indah, R. N. (2020). Hubungan kadar feritin serum dengan kadar enzim SGOT dan SGPT pada pasien thalasemia β mayor. *JISK, 11*, 252–257.
Ahmadi, A., Hosseini, S., Dorgalaleh, A., Hassani, S., Tabibian, S., Tavasoli, B., et al. (2024). Natural anticoagulant protein levels in patients with beta-thalassemia major: A case-control study. *Journal of Hematology, 13*, 23–28.
Ahmed, M. M., Hamid Al-Hakeem, A., & Saad Al-Abeadi, R. (2022). Overview on thalassemia: A review article. *Medical Science Journal for Advance Research, 3*, 26–32.
Ali, S., Mumtaz, S., Shakir, H. A., Khan, M., Tahir, H. M., Mumtaz, S., et al. (2021). Current status of beta-thalassemia and its treatment strategies. *Molecular Genetics & Genomic Medicine, 9*, e1788.
Al-Moshary, M., Imtiaz, N., Al-Mussaed, E., Khan, A., Ahmad, S., & Albqami, S. (2020). Clinical and biochemical assessment of liver function test and its correlation with serum ferritin levels in transfusion-dependent thalassemia patients. *Cureus*.
Almuttrek, A. J. M., Karaipekli, A., Abbas, H. J., & Sabeeh, W. J. (2023). Biochemical assessment of iron overload effect on human organs (liver, heart, brain) in patients with beta-thalassemia major and thalassemia intermediate. *Journal of Population Therapeutics and Clinical Pharmacology, 30*.
Amannila, V. N., Novilla, A., & Gunawan, T. (2024). Hubungan frekuensi dan lamanya transfusi darah dengan kadar ferritin pada pasien talasemia di Rumah Sakit TK II Dustira Cimahi. *Universitas Jenderal Achmad Yani Cimahi, 4*(1), 307–314.
Ansharullah, B. A., Sutanto, H., & Romadhon, P. Z. (2025). Thalassemia and iron overload cardiomyopathy: Pathophysiological insights, clinical implications, and management strategies. *Current Problems in Cardiology, 50*, 102911.
Ayulinda, C. N. F., Yusuf, S., Herdata, H. N., Darnifayanti, Haris, S., & Bakhtiar. (2022). Correlation of increased serum ferritin with SGOT, SGPT, and albumin levels in children with β-thalassemia major. *Archives of Pediatric Gastroenterology, Hepatology and Nutrition, 1*, 1–7.
Aziz, A., Sayed, S., Ismail, D., & Mohamed, Z. (2022). Hematological parameters in beta thalassemia major children. *Minia Journal of Medical Research, 33*, 167–170.
Barton, J. C., & Parker, C. J. (2024). Hemochromatosis. In R. T. Means, G. M. Rodgers, B. Glader, D. A. Arber, F. R. Appelbaum, A. Dispenzieri, T. A. Fehniger, L. C. Michaelis, & J. P. Leonard (Eds.), *Wintrobe’s clinical hematology* (pp. 1378–1404). Wolters Kluwer.
Beudeker, B. J. B., Groothuismink, Z. M. A., van der Eijk, A. A., Debes, J. D., & Boonstra, A. (2022). Circulating cytokines reflect the etiology-specific immune environment in cirrhosis and HCC. *Cancers, 14*, 4900.
Bhalodiya, V. R., Valiya, L. G., Mehta, N. A., & Padhariya, B. B. (2023). Correlation of serum ferritin level in transfusion-dependant thalassemia major patients: A study at a medical college affiliated hospital in Gujarat region. *International Journal of Contemporary Pediatrics, 10*, 330–333.
bioMérieux. (2021). *VIDAS Ferritin*. bioMérieux Clinical Diagnostics.
Chiluka, S., Blessy, P. P. S., Shanmuga, S. M., & Rajashekar, K. (2023). Clinical profile of transfusion-dependent thalassemia major children with reference to serum ferritin and liver function: A prospective observational study. *Asian Journal of Medical Sciences, 14*, 260–265.
Crawford, D. H. G., Ramm, G. A., Bridle, K. R., Nicoll, A. J., Delatycki, M. B., & Olynyk, J. K. (2023). Clinical practice guidelines on hemochromatosis: Asian Pacific Association for the Study of the Liver. *Hepatology International, 17*, 522–541.
Dahlan, S. M. (2018). *Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan*. Salemba Medika.
Das, L., Mohapatra, A. P., Pradhan, P. A., & Upadhyay, S. K. (2023). Clinical profile and outcome of children with thalassemia admitted to a tertiary care teaching hospital: An observational study. *Research and Reviews in Pediatrics, 24*, 63–66.
Dewi, S. R. P., Septhimoranie, S., & Muchzal, S. (2021). Correlation of saliva characteristics and caries in beta-thalassemia major patients. *Majalah Kedokteran Gigi Indonesia, 6*, 100.
Dewiyanti, E., Aditiawati, A., & Sari, D. P. (2021). Serum ferritin levels and endocrine disorders in children with thalassemia major. *Paediatrica Indonesiana, 61*, 125–132.
Dissanayake, R., Samarasinghe, N., Waidyanatha, S., Pathirana, S., Neththikumara, N., Dissanayake, V. H. W., et al. (2022). Assessment of iron overload in a cohort of Sri Lankan patients with transfusion dependent beta thalassaemia and its correlation with pathogenic variants in HBB, HFE, SLC40A1, and TFR2 genes. *BMC Pediatrics, 22*, 344.
Dorgalaleh, S., Barahouie, A., Naghipoor, K., Dastaviz, F., Ghodsalavi, Z., & Oladnabi, M. (2020). Transfusion related adverse effects on beta-thalassemia major and new therapeutic approaches: A review study. *International Journal of Pediatrics*.
Drago, V. N., Dajnowicz, S., Parks, J. M., Blakeley, M. P., Keen, D. A., Coquelle, N., et al. (2022). An N⋯H⋯N low-barrier hydrogen bond preorganizes the catalytic site of aspartate aminotransferase to facilitate the second half-reaction. *Chemical Science, 13*, 10057–10065.
Faranoush, M., Faranoush, P., Heydari, I., Foroughi-Gilvaee, M. R., Azarkeivan, A., Parsai Kia, A., et al. (2023). Complications in patients with transfusion dependent thalassemia: A descriptive cross-sectional study. *Health Science Reports, 6*, 1–10.
Farmakis, D., Eleftheriou, A., & Bain, B. (2022). *Management of transfusion dependent thalassaemia* (4th ed.). Thalassaemia International Federation.
Faruqi, A., Zafar, T., Subuctageen, S., & Mughal, I. A. (2024). Iron overload and liver function in patients with beta thalassemia major: A cross-sectional study. *Pakistan Journal of Medical Sciences, 40*, 2000–2004.
Hoffbrand, A. V., & Steensma, D. P. (2020). *Hoffbrand’s essential haematology* (8th ed.). Wiley.
Hussain, G., Abdullah, M., & Hussein, N. (2023). Association of the changes in hepatic enzymes, bilirubin, and plasma proteins with beta-thalassemia in iron overloaded-patients. *Journal of Advanced Biotechnology and Experimental Therapeutics, 6*, 429.
Husseiny, I., & Jumaili, E. F. (2025). Comparative analysis of the age, gender, and ferritin levels with hepcidin in Iraqi patients suffering beta thalassemia (major and intermedia). *HAYATI Journal of Biosciences, 32*, 1518–1528.
Ibrahim, A. S., Abd El-Fatah, A. H., Abd El-Halim, A. F., & Mohamed, F. F. (2023). Serum ferritin levels and other associated parameters with diabetes mellitus in adult patients suffering from beta thalassemia major. *Journal of Blood Medicine, 14*, 67–81.
Ibrahim, I., Chung, C. P., & Setia, D. (2024). Pengaruh kadar ferritin terhadap indeks eritrosit (MCH, MCV, MCHC) pada pasien thalasemia di RSUD Dr. Zainoel Abidin. *JKT, 5*, 12420–12428.
Irdawati, I., Syaiful, A. A., & Haryani, A. (2021). Hubungan usia anak penderita thalasemia dengan frekuensi transfusi. *Jurnal Berita Ilmu Keperawatan, 14*, 73–79.
Jabbar, H. F., Attafi, F. J., Kadhim, E. J., & Jarallah, K. R. (2024). Association between serum ferritin level and liver function tests in children with beta-thalassemia (Thalassemia Center of Kut Hospital, Iraq). *EJMHR, 2*, 166–170.
Jabbar, H. K., Hassan, M. K., & Al-Naama, L. M. (2023). Lipids profile in children and adolescents with β-thalassemia major. *Hematology, Transfusion and Cell Therapy, 45*, 467–472.
Joniarti, F., Rofinda, Z. D., & Husni. (2022). Korelasi kadar feritin dengan enzim transaminase penyandang talasemia beta mayor tergantung transfusi. *Majalah Kedokteran Andalas, 45*, 327–333.
Kementerian Kesehatan Republik Indonesia. (2018). *Pedoman nasional pelayanan kedokteran tata laksana thalasemia*.
Keohane, E. M., Otto, C. N., & Walenga, J. M. (2024). *Rodak’s hematology: Clinical principles and applications* (7th ed.). Elsevier.
Khandros, E., & Kwiatkowsky, J. (2023). Thalassemia syndromes: Quantitative disorders of globin chain synthesis. In R. Means, G. Rodgers, B. Glader, D. Arber, F. Appelbaum, A. Dispenzieri, T. Fehniger, L. Michaelis, & J. Leonard (Eds.), *Wintrobe’s clinical hematology* (pp. 3257–3476). Wolters Kluwer.
Khezri, H. D., Aliasgharian, A., Naderisorki, M., Kosaryan, M., Ghazaiean, M., Fallah, H., et al. (2022). Ferritin thresholds for cardiac and liver hemosiderosis in β-thalassemia patients: A diagnostic accuracy study.
Kotla, N. K., Dutta, P., Parimi, S., & Das, N. K. (2022). The role of ferritin in health and disease: Recent advances and understandings. *Metabolites, 12*, 609.
Lee, J. S., Rhee, T. M., Jeon, K., Cho, Y., Lee, S. W., Han, K. D., et al. (2022). Epidemiologic trends of thalassemia, 2006–2018: A nationwide population-based study. *Journal of Clinical Medicine, 11*.
Lin, M.-S., Lin, H.-S., Chang, M.-L., Tsai, M.-H., Hsieh, Y.-Y., Lin, Y.-S., et al. (2022). Alanine aminotransferase to aspartate aminotransferase ratio and hepatitis B virus on metabolic syndrome: A community-based study. *Frontiers in Endocrinology, 13*, 922312.
Lin, P.-C., Hsu, W.-Y., Lee, P.-Y., Hsu, S.-H., & Chiou, S.-S. (2023). Insights into hepatocellular carcinoma in patients with thalassemia: From pathophysiology to novel therapies. *International Journal of Molecular Sciences, 24*, 12654.
Liu, H., Li, H., Deng, G., Zheng, X., Huang, Y., Chen, J., et al. (2024). Association of AST/ALT ratio with 90-day outcomes in patients with acute exacerbation of chronic liver disease: A prospective multicenter cohort study in China. *Frontiers in Medicine, 11*, 1307901.
Mardhiyah, A., Suzana, M. H., Letcmi, P. S., & Yosep, I. (2023). Psychosocial problems on adolescents with thalassemia major: A systematic scoping review. *KnE Social Sciences*.
Means, R. T., Rodgers, G. M., Glader, B., Arber, D. A., Appelbaum, F. R., Dispenzieri, A., et al. (2024). *Wintrobe’s clinical hematology* (15th ed.). Wolters Kluwer.
Monem, A. A., Shehata, S., Elsayed, M., & Ayad, A. (2021). Descriptive clinical study of children with beta-thalassemia at Damanhour Medical National Institute. *Alexandria Journal of Pediatrics, 34*, 67–73.
Musallam, K. M., Barella, S., Origa, R., Ferrero, G. B., Lisi, R., Pasanisi, A., et al. (2024). Revisiting iron overload status and change thresholds as predictors of mortality in transfusion-dependent β-thalassemia: A 10-year cohort study. *Annals of Hematology, 103*, 2283–2297.
Nanou, A., Toumpeki, C., Fanis, P., Bianchi, N., Cosenza, L. C., Zuccato, C., et al. (2021). Sex-specific transcriptional profiles identified in β-thalassemia patients. *Haematologica, 106*, 1207–1211.
Needs, T., Gonzalez-Mosquera, L. F., & Lynch, D. T. (2025). Beta thalassemia. In *StatPearls*. StatPearls Publishing.
Nemeth, E., & Ganz, T. (2021). Hepcidin-ferroportin interaction controls systemic iron homeostasis. *International Journal of Molecular Sciences, 22*.
Origa, R., & Issa, L. (2024). Beta thalassemia in children: Established approaches, old issues, new non-curative therapies, and perspectives on healing. *Journal of Clinical Medicine, 13*, 6966.
Otto, C. (2024). Hemoglobin metabolism. In E. M. Keohane, C. N. Otto, & J. M. Walenga (Eds.), *Rodak’s hematology: Clinical principles and applications* (7th ed.). Elsevier.
Pinto, V., & Forni, G. (2020). Management of iron overload in beta-thalassemia patients: Clinical practice update based on case series. *International Journal of Molecular Sciences, 21*, 8771.
Rauf, A., Shariati, M. A., Khalil, A. A., Bawazeer, S., Heydari, M., Plygun, S., et al. (2020). Hepcidin, an overview of biochemical and clinical properties. *Steroids, 160*, 108661.
Ricci, C., Abbandonato, G., Giannangeli, M., Matthews, L., Almásy, L., Sartori, B., et al. (2024). Ferritin at different iron loading: From biological to nanotechnological applications. *International Journal of Biological Macromolecules, 276*, 133812.
Rifai, N., Chiu, R. W. K., Young, I., Burnham, C.-A. D., Wittwer, C., & Tietz, N. W. (Eds.). (2023). *Tietz textbook of laboratory medicine* (7th ed.). Elsevier.
Rujito, L. (2020). *Buku referensi talasemia: Genetik dasar dan penanganan terkini*.
Sadiq, I. Z., Abubakar, F. S., Usman, H. S., Abdullahi, A. D., Ibrahim, B., Kastayal, B. S., et al. (2024). Thalassemia: Pathophysiology, diagnosis, and advances in treatment. *Thalassemia Reports*.
Safitri, T. Y., Setiawan, L., Arkhaesi, N., & Widyastiti, N. S. (2024). Association between immune-inflammation index (SII) and ferritin with hepatic function in patients with thalassemia major. *DMJ, 13*, 98–103.
Saleh, N., Allam, T., Hawary, H., & El Borai, N. (2023). Iron overload-induced hepatotoxicity: An overview. *Journal of Current Veterinary Research, 5*, 60–78.
Sanchez, M., Blanquer, M., Moraleda, J. M., Salido, E. J., & Perez-Oliva, A. B. (2022). New insights into pathophysiology of β-thalassemia. *Frontiers in Medicine, 9*.
Saravani, K., Ostadrahimi, P., & Jahanifard, A. (2024). Evaluation of the level of liver enzymes and its relationship with ferritin and the frequency of blood transfusion in patients with thalassemia. *Cellular, Molecular and Biomedical Reports, 4*, 100–110.
Sheth, S. (2023). Thalassemia syndrome. In R. Hoffman, E. J. Benz, L. E. Silberstein, H. E. Heslop, J. I. Weitz, M. E. Salama, & S. A. Abutalib (Eds.), *Hematology: Basic principles and practice* (pp. 555–583). Elsevier.
Sheth, S., & Thein, S. L. (2021). Thalassemia: A disorder of globin synthesis. In K. Kaushansky, J. T. Prchal, L. J. Burns, M. A. Lichtman, M. Levi, & D. C. Linch (Eds.), *Williams hematology* (10th ed.). McGraw-Hill Education.
Taher, A. T., Musallam, K. M., & Cappellini, M. D. (2021). β-Thalassemias. *The New England Journal of Medicine, 384*, 727–743.
Tamber, S. S., Bansal, P., Sharma, S., Singh, R. B., & Sharma, R. (2023). Biomarkers of liver diseases. *Molecular Biology Reports, 50*, 7815–7823.
Tatu, T. (2020). Laboratory diagnosis of β-thalassemia and HbE. In M. Zakaria & T. Hassan (Eds.), *Beta thalassemia*. IntechOpen.
Taufiq, N. I., Suherlan, E., & Firdaus, F. A. (2019). Correlation of serum ferritin levels with activity enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in β-thalassemia major patients in Dr. Slamet Garut RSUD period 2017–2018. *Prosiding Pendidikan Dokter, 5*.
Tayal, A., Kaur, J., Sadeghi, P., & Maitta, R. W. (2025). Molecular mechanisms of iron metabolism and overload. *Biomedicines*.
Tesio, N., & Bauer, D. E. (2023). Molecular basis and genetic modifiers of thalassemia. *Hematology/Oncology Clinics of North America, 37*, 273–299.
Testa, U., Pelosi, E., & Castelli, G. (2025). Outline of iron metabolism, with emphasis to erythroid cells: Iron metabolism. *Mediterranean Journal of Hematology and Infectious Diseases, 17*, e2025067.
Tripathi, P. (2023). Genetics of thalassemia. In *The erythrocyte—A unique cell* (pp. 1–12). IntechOpen.
Tuo, Y., Li, Y., Li, Y., Ma, J., Yang, X., Wu, S., et al. (2024). Global, regional, and national burden of thalassemia, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. *eClinicalMedicine, 72*, 102619.
Villavicencio Kim, J., & Wu, G. Y. (2020). Body building and aminotransferase elevations: A review. *Journal of Clinical and Translational Hepatology, 8*, 161–167.
Vogt, A.-C. S., Arsiwala, T., Mohsen, M., Vogel, M., Manolova, V., & Bachmann, M. F. (2021). On iron metabolism and its regulation. *International Journal of Molecular Sciences*.
Wahidiyat, P. A., Sari, T. T., Rahmartani, L. D., Setianingsih, I., Iskandar, S. D., Pratanata, A. M., et al. (2020). An insight into Indonesian current thalassaemia care and challenges. *ISBT Science Series, 15*, 334–341.
Wahidiyat, P. A., Yo, E. C., Wildani, M. M., Triatmono, V. R., & Yosia, M. (2021). Cross-sectional study on knowledge, attitude and practice towards thalassaemia among Indonesian youth. *BMJ Open, 11*, e054736.
Weiskirchen, R. (2025). From spark to wildfire: How hyperferritinemia fans the flames of metabolic dysfunction-associated steatotic liver disease. *Exploration of Digestive Diseases, 4*, 100599.
Wong, E. C., Brugnara, C., Straseski, J., Kellogg, M., & Adeli, K. (2021). *Pediatric reference intervals* (8th ed.). Academic Press.
Yusuf, S., Herdata, H. N., Edward, E. D., & Khairunnisa, K. (2023). Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes. *F1000Research, 12*, 154.
Yutarti, C. S., & Susilowati, I. T. (2023). Hubungan kadar feritin serum dengan tes fungsi hati pada pasien thalasemia mayor. *JK, 14*, 42–48.
Zainab, S., & Ali, A. H. G. (2022). Detection of enzymatic levels in patients with thalassemia in Dewanyah Province. *Journal of Pharmaceutical Negative Results*, 1977–1984.
Zakaria, M., Hassan, T., Sherief, L., & Erhabor, O. (Eds.). (2023). *Thalassemia syndromes—New insights and transfusion modalities*. IntechOpen.
DOI: https://doi.org/10.33024/mahesa.v6i10.25061
Refbacks
- Saat ini tidak ada refbacks.
Publisher: Universitas Malahayati Lampung

Semua artikel dapat digunakan dibawah lisensi Creative Commons Attribution-ShareAlike 4.0 International License


Panduan Penulisan





